Jeong Yoon Suh

Jeong Yoon Suh

Auto-generated profile, based on publicly available information

Jeong Yoon Suh

Department of Medicine, College of Medicine, Chung-Ang University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in The Korean Journal of Urological Oncology
Verified
Journal Article
Open access
PDF file
JSJeong Yoon Suh
Jeong Yoon Suh
SMSe Jung Maeng
Se Jung Maeng
MKMirinae Kim
Mirinae Kim
SKSu Jeong Kang
Su Jeong Kang
YCYoung Wook Choi
Young Wook Choi
ICIn Ho Chang
In Ho Chang
Clear cell renal cell carcinoma (ccRCC) is a disease with a wide variety of clinical progressions such as the rate of disease progression or the degree of metastasis. About 30% of ccRCC patients suffer from metastatic diseases, and about 30% develop metastasis after diagnosis. In the case of metastatic RCC, early prediction of the disease is important because of the poor prognosis, but ccRCC-specific molecular markers for clinical use are not available yet. As an alternative, liquid biopsy, which can find molecules released from tumor tissues in circulating blood and obtain information on metastatic dissemination and recurrence of ccRCC, is emerging. In this article, we will introduce molecules such as cell free DNA, cell free RNA, protein, and exosomes available as circulating biomarkers for liquid biopsy. We will also introduce some promising technologies that can compensate for the limitations of liquid biopsy.

31 August 2022 in The Korean Journal of Urological Oncology
Verified
Journal Article
Open access
PDF file
JHJae Baek Ha
Jae Baek Ha
JJJaewoon Jeong
Jaewoon Jeong
JSJeongyoon Suh
Jeongyoon Suh
SPSungyun Park
Sungyun Park
RWRuei Ting Wang
Ruei Ting Wang
SCSe Young Choi
Se Young Choi
The development of lab-on-a-chip technology based on microfluidics has been used from diagnostic test to drug screening in biomedical science. Lab-on-a-chip technology is also being expanded to the concept of an organ-on-a-chip with the development of cell biology and biocompatible material development. In addition, artificial intelligence (AI) has brought dramatic changes over the past few years in science, industry, defense, science and healthcare. AI-generated output is beginning to prove comparable or even superior to that of human experts. Lab-on-a-chip technology in specific microfluidic devices can overcome the above bottlenecks as a platform for building and implementing AI in a large-scale, cost-effective, high-throughput, automated and multiplexed manner. This platform, high-throughput imaging, becomes an important tool because it can generate high-content information which are too complex to analyze with conventional computational tools. In addition to the capabilities of a data provider, lab-on-a-chip technology can also be leveraged to enable AI developed for the accurate identification, characterization, classification and prediction of objects in heterogeneous samples. AI will provide quantitative and qualitative analysis results close to human in the urology field with lab-on-a-chip.